Ken Griffin Novartis Ag Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novartis Ag stock. As of the latest transaction made, Citadel Advisors LLC holds 353,100 shares of NVS stock, worth $38.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

353,100

Previous 395,600 10.74%

Holding current value

$38.6 Million

Previous $45.5 Million 24.49%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$96.78 - $117.18 $39.3 Million - $47.6 Million	406,007 Added 222.86%	588,188 $57.2 Million
Q3 2024 Nov 14, 2024	SELL	$106.13 - $120.89 $6.83 Million - $7.78 Million	-64,380 Reduced 26.11%	182,181 $21 Million
Q2 2024 Aug 14, 2024	SELL	$92.57 - $107.37 $29.2 Million - $33.9 Million	-315,524 Reduced 56.13%	246,561 $26.2 Million
Q1 2024 May 15, 2024	BUY	$95.27 - $108.47 $11.6 Million - $13.2 Million	122,030 Added 27.73%	562,085 $54.4 Million
Q4 2023 Feb 14, 2024	BUY	$92.27 - $101.54 $40.6 Million - $44.7 Million	440,055 New	440,055 $44.4 Million
Q2 2023 Aug 14, 2023	BUY	$92.52 - $104.91 $137,577 - $156,001	1,487 Added 854.6%	1,661 $167,000
Q1 2023 May 15, 2023	SELL	$80.03 - $92.81 $3.33 Million - $3.86 Million	-41,591 Reduced 99.58%	174 $16,000
Q4 2022 Feb 14, 2023	SELL	$75.55 - $92.52 $7.43 Million - $9.1 Million	-98,408 Reduced 70.2%	41,765 $3.79 Million
Q3 2022 Nov 14, 2022	BUY	$74.61 - $87.26 $5.8 Million - $6.79 Million	77,778 Added 124.65%	140,173 $10.7 Million
Q2 2022 Aug 15, 2022	BUY	$80.52 - $93.75 $4.68 Million - $5.45 Million	58,105 Added 1354.43%	62,395 $5.27 Million
Q1 2022 May 16, 2022	SELL	$80.11 - $90.62 $23.1 Million - $26.1 Million	-287,988 Reduced 98.53%	4,290 $376,000
Q4 2021 Feb 14, 2022	BUY	$79.7 - $88.13 $9.55 Million - $10.6 Million	119,816 Added 69.47%	292,278 $25.6 Million
Q3 2021 Nov 15, 2021	SELL	$81.78 - $95.14 $10.1 Million - $11.8 Million	-123,872 Reduced 41.8%	172,462 $14.1 Million
Q2 2021 Aug 16, 2021	BUY	$85.24 - $94.15 $20.5 Million - $22.7 Million	240,836 Added 433.95%	296,334 $27 Million
Q1 2021 May 17, 2021	SELL	$83.5 - $98.47 $7.99 Million - $9.43 Million	-95,723 Reduced 63.3%	55,498 $4.74 Million
Q4 2020 Feb 16, 2021	BUY	$78.07 - $94.43 $9.85 Million - $11.9 Million	126,129 Added 502.67%	151,221 $14.3 Million
Q3 2020 Nov 16, 2020	SELL	$82.14 - $91.0 $4.66 Million - $5.16 Million	-56,719 Reduced 69.33%	25,092 $2.18 Million
Q1 2020 May 15, 2020	BUY	$70.67 - $99.01 $4.74 Million - $6.65 Million	67,135 Added 457.45%	81,811 $6.75 Million
Q4 2019 Feb 14, 2020	SELL	$84.35 - $95.37 $3.41 Million - $3.85 Million	-40,413 Reduced 73.36%	14,676 $1.39 Million
Q3 2019 Nov 14, 2019	SELL	$85.54 - $94.26 $43.9 Million - $48.3 Million	-512,656 Reduced 90.3%	55,089 $4.79 Million
Q2 2019 Aug 14, 2019	BUY	$75.4 - $92.8 $30.8 Million - $37.9 Million	407,983 Added 255.37%	567,745 $51.8 Million
Q1 2019 May 15, 2019	SELL	$75.32 - $86.15 $7.58 Million - $8.67 Million	-100,651 Reduced 38.65%	159,762 $0
Q4 2018 Feb 14, 2019	SELL	$73.66 - $82.02 $38.7 Million - $43.1 Million	-525,834 Reduced 66.88%	260,413 $20 Million
Q3 2018 Nov 13, 2018	BUY	$66.94 - $77.43 $49.7 Million - $57.5 Million	743,131 Added 1723.56%	786,247 $0
Q2 2018 Aug 10, 2018	SELL	$64.91 - $73.36 $1.97 Million - $2.23 Million	-30,400 Reduced 41.35%	43,116 $0
Q1 2018 May 11, 2018	SELL	$70.39 - $84.15 $1.59 Million - $1.9 Million	-22,604 Reduced 23.52%	73,516 $5.94 Million
Q4 2017 Feb 09, 2018	BUY	$72.33 - $77.64 $6.95 Million - $7.46 Million	96,120	96,120 $8.07 Million

Others Institutions Holding NVS

# of Institutions

1,474

Shares Held

134M

Call Options Held

1.31M

Put Options Held

1.56M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $235B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account